These results demonstrate a synergistic relationship between inhibitors of the Rho/MRTF-pathway and trametinib in suppressing NRAS mutant melanoma, whereas the effects of the non-targeted agent vinblastine and trametinib are additive. The gene discussed is RHO; the disease is melanoma.